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RESEARCH IN CONTEXT 
 
Evidence before this study 
Radiotherapy is an effective modality to treat aggressive lymphomas, and e.g. widely used to 
shorten the duration of chemotherapy in patients with localized DLBCL. However, especially 
the role of consolidation radiotherapy for advanced aggressive lymphomas is not based on 
randomized clinical data and overall poorly defined. This includes different definitions of 
bulky disease, and includes extrapolations from extranodal disease manifestations. In 
addition, PET is nowadays implemented in the daily management of patients with DLBCL. 
The available evidence from largely retrospective and uncontrolled trials and a comparably 
diverse practice is conglomerated into the current ESMO and NCCN guidelines. However, 
they are of limited value when one needs to consider consolidation radiotherapy in an 
individual patient. A previous meta-analysis on few trials showed that radiotherapy does not 
improve survival for localized stages and suggested besides new technologies its addition to 
systemic therapy with biologic agents. In order not to repeat the methological problems of the 
recently failed attempts to improve the outcome of R-CHOP, the standard systemic first-line 
therapy of DLBCL, we conducted this comprehensive meta-analysis to assess the impact of 
consolidation radiotherapy in DLBCL. The 11 trials that assessed the role of consolidation 
radiotherapy in a randomized manner as part of the first-line therapy, were identified by a 
systematic search of Pubmed, Embase, Cochrane, and abstracts from ASCO, ASH, ESMO 
and ASTRO published from June 1966 and December 2018.  
Added value of this study 
The existing evidence on the role of consolidation radiotherapy is poorly reflected in the 
current guidelines. This cumulative meta-analysis incorporated the best currently available 
data provided by randomized controlled trials and revealed that consolidation radiotherapy 
does not improve the outcome in unselected DLBCL patients. None of the trials used a PET-
guided approach, and a considerable heterogeneity and a mixed quality in the available body 
of literature has been spotted. The analysis points to the need of a well-designed randomized 
trial to firmly define a role of consolidation radiotherapy in the first-line therapy of DLBCL 
patients. 
Implication of all the available evidence 
Based on the available data and common practice backed up by circumstantial evidence, we 
conclude that in particular, patients with a complete morphologic remission after 
chemotherapy and initial bulky disease are unlikely to profit from consolidation radiotherapy. 
To know which patients could benefit from consolidation radiotherapy, a future clinical 
superiority trial can be envisaged in which patients with PET-positive rests get consolidation 
radiotherapy in a randomized manner. Such a trial on a relevant question would require a 
large number of patients in a collaborative, fully academic trial. This meta-analysis could 
inform colleagues and provide the rational when such a future clinical trial is planned.  
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ABSTRACT 
Rituximab has improved response rates and overall survival in B-cell lymphoma (DLBCL). 
Radiotherapy is an effective treatment modality for lymphomas, but there is uncertainty on its 
use as consolidation after chemo-immunotherapy mainly in advanced stages. 
We evaluated its efficacy with a comprehensive meta-analysis and a systematic search of 
Pubmed, Embase, Cochrane, and abstracts from ASCO, ASH, ESMO and ASTRO published 
from June 1966 and December 2018.  
We identified 11 trials that evaluated consolidation radiotherapy following chemotherapy in a 
randomized fashion in 4’584 patients. The primary endpoint of this meta-analysis was PFS. 
As three of the eleven trials were retracted, this data is based on 2414 patients. For the 
primary endpoint (PFS), we found a hazard ratio (HR) of 0.77 (0.51 to 1.17, pooled (tau2: 
0.25; I2: 85%), and a HR of 0.80 (0.53 to 1.21, pooled (bivariate meta-analysis). For overall 
survival, the HR is 0.93 (0.61 to 1.40; pooled (tau2: 0.25; I2: 74%) and 0.86 (0.58 to 1.27) in a 
bivariate meta-analysis. The lack of benefit did not change over time (p-value: 0.95 (tau2: 
0.32; I2: 88%), and was also absent for PFS when stratifying for chemotherapy, the use of 
Rituximab, age, the dose of radiotherapy, application to patients in complete remission and 
with bulky disease. None of the trials used a PET-guided approach. 
This meta-analysis revealed no survival benefit when consolidation radiotherapy is given to 
unselected DLBCL patients following chemotherapy. These results need to be considered in 
future trials in the PET-CT era. 
 
 
INTRODUCTION 
 
With 35% of all Non-Hodgkin lymphomas (NHL), diffuse large B-cell lymphoma (DLBCL) is 
the most common aggressive lymphoma in adults. The current standard therapy R-CHOP 
cures two-thirds of patients.1,2 Several attempts with a variety of approaches including the 
addition of new drugs have so far failed to improve these results.3,4 Radiotherapy is an 
effective treatment option for patients with aggressive lymphomas. Moving from the primary 
modality for various lymphomas, radiotherapy was later used as a consolidation when the 
anthracycline-containing regimens became available in the 1980s, and is now commonly 
used in localized disease.5 As such, consolidation radiotherapy is part of the first line 
treatment of DLBCL in the ESMO6 and the NCCN guidelines 
(https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf (last access: Nov 28, 2019, 
table S1). However, significant conceptual issues on its current use outside a clinical trial 
remain. They include different definitions of bulky disease, the use in advanced stages, and 
the recent implementation of PET-CT in the clinical management. Albeit not limited to 
consolidation radiotherapy in DLBCL, treatment recommendations are often built on 
experience, clinical judgment and guidelines, but ideally should be based on data, preferably 
from randomized trials. Here we present a comprehensive meta-analysis to assess the 
impact of radiotherapy in addition to and after first-line chemo-immunotherapy of DLBCL 
based on the best currently available data by randomized controlled trials (RCTs). With this 
largest meta-analysis, we aim to provide the rational basis for a future randomized trial on 
the use of consolidation radiotherapy in DLBCL. 
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METHODS 
 
Literature search 
 
We performed a comprehensive search in electronic databases (Pubmed, Embase, 
Cochrane) in any language between June 1966 and December 2018 for randomized 
controlled trials. As the data presented on meetings may differ from the peer-reviewed 
publications,7 a manual search was done of abstracts from ASCO, ASH, ESMO, and ASTRO 
proceedings between 2009 and 2018. We used the following search strategy: (((radiation 
therap*[Title] OR radiotherapy*[Title] OR radio-therap*[Title]))) AND ((non-hodgkin*[Title] OR 
non Hodgkin*[Title] OR nonhodgkin[Title] OR no Hodgkin*[Title] OR nhl[Title] ) OR 
(lymphoma*[Title]) AND ((aggressive[Title] OR malignant[Title] OR advanced[Title] OR 
histiocytic[Title] OR diffuse[Title] OR undifferentiated[Title] OR mixed[Title] OR high 
grade[Title] OR centroblastic [Title] OR immunoblastic[Title]))). 
 
Inclusion criteria and trial selection 
 
Three investigators independently screened the studies. The flow diagram according to the 
PRISMA statement8,9 depicted in figure 1 illustrates the search and selection process. We 
aimed at identifying randomized trials that had enrolled at least 50 adult patients (≥18 years 
of age) per arm with newly diagnosed DLBCL (or aggressive lymphomas) at any stage 
according to the Ann Arbor classification. Patients had to be treated with a CHOP based 
chemotherapy (+/- rituximab), and randomized to subsequent consolidation radiotherapy or 
no radiotherapy. The 50-patients cut-off was chosen to exclude therapeutic exploratory trials. 
Although the cut-off is arbitrary, it is safe to assume that no confirmatory trials are excluded 
given the high (progression-free) survival rates observed in this population. Patients with 
previously treated or relapsed DLBCLs were excluded. The full text report of identified trials 
was independently checked by the three investigators. Disagreements regarding trial 
selection were discussed until consensus was found. Each report was scrutinized to 
eliminate duplicates and to ensure that it was published as an original article. 
 
Outcome measures 
 
Progression-free survival (PFS) and overall survival (OS) were the outcomes of interest. PFS 
was considered as tumor progression i.e. growth of the tumor during treatment, relapse i.e. 
growth after previous shrinkage or stabilization, or death. For trials that did not report 
outcome data that fit this definition, we used data of an outcome that was as close as 
possible to this definition e.g. event-free survival. 
 
Data extraction 
 
Data extraction was done in duplicate and disagreements was resolved by consensus. We 
used the Cochrane ‘Risk of Bias’ approach to assess methodological quality of trials.10 We 
used the data from the original publications, from intention-to-treat analyses, and from 
randomized patients only, and for the longest follow-up available for a particular outcome. 
The hazard ratio (HR) was used as effect measure for both outcomes. If HR and a measure 
of precision (standard error, variance, or confidence interval) was not available, we digitized 
Kaplan-Meier curves, reconstructed the underlying time-to-event data, and calculated (log) 
 
5
HRs and standard errors using a Cox regression model. Details on the outcome data of the 
11 trials is shown in table 2.  
 
Statistical analysis 
 
Outcome data were pooled with a random-effects model using restricted maximum 
likelihood. We also did bivariate meta-analysis considering both outcomes in one analysis. 
Correlation between OS and PFS was estimated from two of the identified trials.11,12 We 
performed random-effects meta-regression for progression-free survival over time using the 
mid of enrolment period as an independent covariate. Stratified analyses to explore possible 
reasons for heterogeneity were also done using meta-regression. Analyses were done using 
Stata (StataCorp. 2017. Stata Statistical Software: Release 16. College Station, TX: 
StataCorp LLC). Taking into account criticisms of meta-analysis,8,9 the supplemental 
appendix provides additional details on the analysis methods used and all outcome data. The 
latter, used in the meta-analysis, is provided in table 2. 
 
 
RESULTS 
 
After deduplication, our search strategy generated 3’181 references (figure 1). With the aim 
to identify clinical trials that assessed the role of consolidation radiotherapy in a randomized 
manner as part of the first-line therapy, our search revealed 11 trials amenable for this meta-
analysis (details in table 1). Three of the four trials published by Aviles13-16 on this topic have 
later been retracted.14-16 As of September 2019, these retracted papers have together 
received a total of 39 citations. Their data are provided in the respective figures, but were 
excluded from the meta-analyses. One trial was stopped early when the benefit of rituximab 
became evident,12 or as a result of a planned interim analysis.17 Older trials included 
lymphomas classified by the Kiel classification18 or included DLBCLs according to the 
Working Formulation.19 Six of the trials included patients with localized disease only, but five 
of the 11 trials included also advanced stages. With the exception of the GELA LNH 93-111 
where ACVBP instead of CHOP was given in the comparator arm or SWOG,20 where the 
non-irradiated patients received 8 cycles of CHOP (instead of 3), the same chemotherapy 
was given to the randomized patients. The current standard R-CHOP was used in four of the 
11 trials.15-17,21,22 Only the recent Lysa/GOELAMS 02 03 trial21 used PET, although not for 
guided treatment. Radiotherapy was given to both localized stages I & II, but also advanced 
disease, and either to all or only patients in complete remission or bulky disease. GOELAMS 
02 0321 was a non-inferiority trial whereas all other trials used for this meta-analysis used a 
superiority design. 
 
Seven trials with a total of 2’488 patients contributed to the analysis of the primary endpoint 
PFS (figure 2). Data were extracted from the original publications. The UNFOLDER trial has 
been presented in part at the 12th International Congress on Malignant Lymphomas,17 and 
again at ASCO 2018,22 albeit with different endpoints. The latter have been used for this 
meta-analysis. Data from Engelhard18 was not available for the PFS analysis (table 2). For 
PFS, the pooled HR was 0.77 (95% CI: 0.51 to 1.17), and 0.80 (0.53 to 1.21) in the pooled 
bivariate meta-analysis (figure 2). For OS, eight trials with a total of 2744 patients were 
included. The pooled HR was 0.93 (0.61 to 1.40) and 0.86 (0.58 to 1.27) in the bivariate 
meta-analysis (figure 3). Between-trial heterogeneity was high for both outcomes (PFS, tau2: 
0.25, I2: 85%; OS, tau2: 0.25, I2: 74%). The total of 4’584 patients included in this meta-
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analysis were recruited between 1983 and 2013. However, the lack of benefit of the 
combined treatment modality remained stable over time, and time alone cannot explain the 
observed heterogeneity in the meta-analysis (p-value for time trend: 0.95; tau2: 0.32; I2: 88%; 
figure 4).  
 
Given the significant heterogeneity (see also table 1), we analyzed the data by using the 
following stratifications: 1) whether the applied chemotherapy was similar in both arms, 2) 
whether rituximab was used, 3) the dose of radiotherapy, and 4) whether it was given only in 
complete morphologic remission. In addition, we stratified according to the following trial 
population characteristics: 5) mean age of the treated patients, 6) whether the majority had 
advanced stage, and 7) whether the majority had bulky disease. As shown in figure 5, we 
failed to explain between-trial heterogeneity by stratifying on any of these subgroups. 
 
 
DISCUSSION 
 
We here provide a large and comprehensive meta-analysis with the best currently available 
data from randomized trials on consolidation radiotherapy in the first-line treatment of 
aggressive lymphomas. In summary, we find no evidence for a survival benefit of an 
unselected consolidation radiotherapy for these patients, but uncertainty remains high. 
 
Our analysis extends the data from both retrospective and uncontrolled series in favor2,23-25 
or against26 the use of consolidation radiotherapy in the first line setting. Our state-of-the art 
and updated meta-analysis that takes into account general concerns on the reproducibility of 
meta-analysis8,9 and significantly corroborates a previous meta-analysis on a limited number 
of trials.27 It also goes beyond extrapolations from data on particular extranodal sites,28 the 
common use of consolidation radiotherapy for limited clinical stages only,23 pretreatment with 
different chemotherapy,29 or to treat bulky disease only.2 Collectively, the latter data are the 
basis for the current recommendations on the combined treatment modality also for patients 
with advanced stages. They have created an unsatisfactory uncertainty and rather experts’ 
opinions on the use of radiotherapy when facing an individual patient. However, DLBCL is a 
disease in which cure, but also treatment-related toxicities and economic factors have to be 
considered. Unfortunately, our meta-analysis cannot provide data on costs, safety and long 
term risks of secondary malignancies related to radiation therapy.  
 
Overall, the data that could be used for this meta-analysis is of mixed quality (tables 1 & 2). 
As an extreme, three of the four randomized trials by the same group all clearly supporting 
the added value of radiotherapy have later been retracted, the last one in early 2019.14-16 We 
display their results in our figures as they might have influenced the use of consolidation 
radiotherapy in routine practice or clinical trials before their retraction. The results of the 
important UNFOLDER trial is still not fully published.17,22 The trials used for this meta-
analysis also harbor considerable conceptual heterogeneity: radiotherapy was given to 
shorten chemotherapy and its toxicity, to improve the outcome of the first-line 
treatment11,12,17,22 or as a salvage option for patients who achieved only a partial remission 
after chemotherapy.14,21 As the Korean “ASPIRE” trial was unfortunately later withdrawn 
(NCT02054559; 3 x R-CHOP + radiotherapy vs. 6 x R-CHOP for stage I & II DLBCL), there 
is currently no randomized trial supporting the widely used and recently updated and safe 
approach to give less chemotherapy and PET-guided radiotherapy to patients with localized 
DLBCL.5,23,30-33 Also the data on limited stage DLBCL which accounts for 30 % of the cases, 
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harbor significant variability as different definitions for limited stage, bulky disease as well as 
risk stratification and extrapolations were used.2,34 This renders the integration of all available 
results difficult. Furthermore, a detailed view goes beyond the possibilities of a meta-analysis 
analyzing population level data. Although we do not have information on the stage-modified-
IPI20,35 for all trials included in our analysis, we assume that many patients with localized 
disease of this meta-analysis had a low risk disease. They have an excellent prognosis, 
regardless of radiotherapy.36 The FLYER trial established four cycles of R-CHOP to be 
sufficient for patients with favorable risk (and non-bulky) DLBCLs.37 Radiotherapy in this trial 
was limited to the contralateral testis in case of testicular involvement. In the yet unpublished 
OPTIMAL>60 trial (NCT014778542), radiotherapy (and two additional cycles of 
chemotherapy) is given just to PET-positive sites after four cycles of chemotherapy. 
According to an interim analysis, this can compensate the inferior outcome of this 
population.37 Furthermore, the authors of this trial communicated that radiotherapy to PET-
negative bulky disease is not needed.38  
 
In the latest ESMO guidelines, consolidation radiotherapy for DLBCL patients is 
recommended for both elderly and intermediate- and high-risk young patients with bulky 
disease.6 NCCN is less firm, and mainly restricts its recommendation to residual disease 
(partial remission or PET-positivity, table S1). These recommendations are not fully 
supported by the results of this meta-analysis, especially by the results of the stratified 
analysis provided in figure 5. The International Lymphoma Radiation Oncology Group 
(ILROG) has recently updated its guidelines, albeit in the relapsed and refractory setting.39 
The trials analyzed in our meta-analysis did not specifically include patients with extranodal 
DLBCL for which both ESMO40 and ILROG41 have published separate guidelines. 
Specifically, consolidative mediastinal radiotherapy is currently recommended in responding 
PMBL patients after treatment with standard-dose chemoimmunotherapy.40 However, 
extrapolation of the data of our meta-analysis on DLBCL NOS to and from entities such as 
primary mediastinal lymphoma, primary central nervous system (CNS) or testicular 
lymphoma is discouraged. The safe omission of whole brain radiotherapy for CNS 
lymphomas is conceptually controversial.42,43 As the role of adjuvant mediastinal radiotherapy 
in PMBL patients with complete remission after chemotherapy is unclear and a large number 
of patients are cured by chemotherapy alone with DA-EPOCH-R44, it is important to note that 
accrual in IELSG-37 (NCT01599559) has recently been completed; this potentially practice 
changing randomized trial with a non-inferiority design has evaluated the role of 
consolidation radiotherapy in PET-negative patients.  
 
Our meta-analysis provides further evidence that patients with a complete morphologic 
remission after chemotherapy or initial bulky disease are unlikely to particularly profit from 
consolidation radiotherapy.25,38 PET has become an integral part of the treatment of DLBCL 
patients, although the prognostic value of interim PET is limited,45,46 and a PET-based 
escalation of chemotherapy was not able to improve the outcome.47 None of the trials that we 
included in our meta-analysis used a truly PET-guided treatment approach. This was applied 
in limited stage DLBCL in a retrospective32 and also a prospective,30 albeit non-randomized 
trial. In order not to add also radiotherapy to the recent painful flaws in clinical DLBCL 
research,3,4 our meta-analysis should be taken into account when a new trial is planned. We 
provide evidence on patients that we should rather not selectively irradiate, but we still do not 
know how to use consolidation radiotherapy. Besides its wide and established use in 
localized disease,5 we see the rationale use of radiotherapy in DLBCL patients analogous to 
the current situation in Hodgkin’s disease, e.g. for insufficient responses to chemo-
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immunotherapy. Considering retrospective trials,38,48 radiotherapy could be restricted to PET-
positive rests. Among other unanswered questions, this would be practice changing. Ideally, 
this hypothesis needs corroboration in two separate prospective trials to randomly apply 
radiotherapy in trial 1 for patients with PET-negative, and trial 2 for patients with PET-positive 
rests. The first trial would be a non-inferiority trial to proof whether it is safe to not irradiate 
patients perceived to be cancer-free. Trial 2 would be a superiority design testing whether 
radiotherapy is able to improve the outcome residual DLBCL after chemo-immunotherapy. 
Assuming a 2-year PFS, an appropriate and pragmatic endpoint in DLBCL49,50 of 80%, an 
alpha of 0.025 for the non-inferiority (one-sided) and 0.05 (two-sided) for the superiority trial, 
a power of 80% and enrolment over 5 years, we calculated the following sample size: trial 1 
(failure rate of 24% (HR 1.23)), would require 1916 overall or 384 patients per year; trial 2 
(and a HR of 0.75 or an improvement of the 2-year PFS to 85%) would need 1’098 patients 
or 220 patients per year. Assuming an end-of-therapy PET-positivity of 25-30%,45 4’000 or 
5’000 patients respectively have to be screened. Clearly, such numbers need a global and 
fully committed academic effort. However, otherwise the important question on the role of 
consolidation radiotherapy in DLBCL, that with the current data, regularly gives rise to 
unsatisfactory and futile discussions at lymphoma boards, will never be answered 
convincingly. Based on this meta-analysis and other data,21 we favor a superiority trial that 
first allocates a role of consolidation radiotherapy in DLBCL. Then, one may also test the use 
of smaller irradiation volumes according to the concept of involved node versus involved site 
radiotherapy using modern techniques (intensity modulated radiotherapy (IMRT)) to reduce 
doses to organs at risk.31,51 New trials could also approach unanswered questions on the role 
of consolidation radiotherapy in other subpopulations like patients with interim PET positive 
disease, or in limited stage disease of high risk histologies such as double hit lymphomas 
although the prognosis of the later may be better than previously perceived.52  
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Table 1: Summary on the randomized trials used for the meta-analysis 
 
The number of patients in the respective column indicates the actual number of patients for 
the individual trials that received consolidation radiotherapy in a randomized fashion. The 
retracted trials are highlighted in grey. The superscript number in the study column refers to 
the number of the references in the manuscript. 
 
Trial 
(with 
reference) 
Diagnosis Patients 
(#) 
Recruitment 
period 
Mean 
age (y) 
 
Same 
chemotherapy 
in both arms 
Rituximab 
used 
Radiation 
dose 
>30 Gy 
13  Aviles et 
al. 
DLCL 218 1983-1988 59-61 yes no yes 
18  Engelhard 
et al. 
high grade 
NHL 
110 (of 
548) 
1986-1989 56 yes no yes 
19  ECOG 
1484 
diffuse 
aggressive 
NHL 
172 (of 
399) 
1984-1992 59 yes no no 
14  Aviles et 
al. 
DLCL 341 1989-1995 53-57 yes no yes 
20  SWOG 
8736 
intermediate 
& high grade 
NHL 
401 (of 
442) 
1988-1995 59 no no yes 
11  GELA 93-
1 
aggressive 
NHL 
318 (of 
647) 
1993-2000 46-47 no no yes 
12  GELA 93-
4 
aggressive 
NHL 576 1993-2002 68-69 yes no yes 
15  Aviles et 
al. 
PMBL 124 (of 
182) 
2001-2004 32-35 yes yes no 
16  Aviles et 
al. 
DLBCL 
258 (of 
612) 
2006-2010 53 yes yes no 
17,22  
UNFOLDER 
Largely 
DLBCL 
285 2005-2012 44 no yes yes 
21  
GOELAMS 
02 03 
DLBCL 334 2005-2013 56 yes yes yes 
 
Trial Publication 
 
Stages 
 
Bulky disease 
 
Randomized 
 
13  Aviles et al. Int J Radiat Biol 1994 advanced all 
only CR and bulky 
disease 
18  Engelhard et al. Ann Oncol 1991 localized & advanced 19% initially; bulky 
not randomized 
only CR pts 
19  ECOG 1484 J Clin Oncol 2004 localized 31% initially (tumor 
> 10cm) 
only CR pts 
14  Aviles et al. 
Leuk Lymphoma 
2004 
advanced all 
only CR and bulky 
disease 
20  SWOG 8736 
New Engl J Med 
1998 
localized 
number unknown, 
some initially 
all 
11  GELA 93-1 
New Engl J Med 
2005 localized 
12% of RT pts.; 10% 
of non-RT pts all 
12  GELA 93-4 J Clin Oncol 2007 localized 9% of RT pts; 8% of 
non-RT pts. 
all 
15  Aviles et al. Int J Radiat Biol 2012 localized 94% of RT pts. only CR pts 
16  Aviles et al. Hematology 2018 advanced 30 % of RT pts. 
only CR and bulky 
disease 
17,22  UNFOLDER 
(12-ICML;a122); 
ASCO 2018;a7574 
localized & advanced 76 % initially 
initially 4 arms; 
random for RT only 
in CR pts. 
21  GOELAMS 02 03 Blood 2018 localized 
for non-bulky disease 
only 
random at start, some 
PR pts. received RT 
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Table 2: Outcome data of the individual trials used for the meta-analysis 
Correlation between progression-free and overall survival were done for the GELA trial. The 
superscript number in the study column refers to the number of the references in the 
manuscript. Abbreviations: HR, hazard ratio; ln, natural logarithm; SE, standard error 
 
Trial 
(with reference) 
Overall survival Progression-free survival 
Hazard ratio ln HR (SE) Hazard ratio ln HR (SE) 
13  Aviles et al. 0.33 -1.11 (0.44) 0.31 ?-1.17 (0.36) 
18  Engelhard et al. 2.09 0.74 (0.58) n/a n/a 
19  ECOG 1484 0.81 -0.21 (0.28) 0.66 ?-0.41 (0.24) 
14  Aviles et al. 0.35 -1.04 (0.25) 0.36 -1.02 (0.22) 
20  SWOG 8736 0.64 -0.44 (0.23) 0.63 -0.46 (0.19) 
11  GELA 93-1 1.98 0.68 (0.20) 1.92 0.65 (0.16) 
12  GELA 93-4 1.08 0.07 (0.14) 1.09 0.09 (0.13) 
15  Aviles et al. 0.21 -1.54 (0.29) 0.31 -1.16 (0.28) 
16  Aviles et al. 0.28 -1.27 (0.32) 0.4 -0.92 (0.28) 
17,22  UNFOLDER 1.2 0.18 (0.38) 0.7 -0.36 (0.20) 
21  GOELAMS 02 03 0.52 -0.66 (0.45) 0.58 -0.54 (0.43) 
 
 
 
Figure legends 
 
Figure 1: Study selection  
Flow diagram according to the PRISMA statement to illustrate the search and selection 
process 
 
Figure 2: Effect of consolidation radiotherapy on progression-free survival 
Circles are proportional to trial size i.e. number of patients; retracted trials are displayed with 
hollow circles 
 
Figure 3: Effect of consolidation radiotherapy on overall survival  
Circles are proportional to trial size i.e. number of patients; retracted trials are displayed with 
hollow circles 
 
Figure 4: Time trend plot on the effect of consolidation radiotherapy 
Circles are proportional to weight in analysis; dashed line shows the fitted linear regression; 
retracted trials are in grey 
 
Figure 5: Stratified PFS analysis on the effect of consolidation radiotherapy 
Circles are proportional to stratum size i.e. overall number of patients in stratum; color of 
circles reflects number of trials in stratum i.e. from black (7 trials) to light grey (1 trial); age, 
stage, and bulky disease are characteristics of the study population and cannot be 
interpreted on the individual participant level (ecological fallacy). 
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SUPPLEMENTAL INFORMATION ON THE STATISTICAL ANALYSIS 
All meta-analyses were done using a random-effects model. Between-trial heterogeneity τ2 was estimated using 
the method proposed by Paule and Mandel1 and as implemented by the empirical Bayes option of the metareg 
command in Stata.2 Confidence intervals were calculated as suggested by Knapp and Hartung3 and prediction 
intervals as suggested by Higgins et al.4 Timetrend and stratified analyses were done using the same methods. 
Bivariate meta-analysis was done using the mvmeta command in Stata (White 2009 and 2011).5,6 If HR and a 
measure of precision (standard error, variance, or confidence interval) was not available, we digitized Kaplan-
Meier curves, reconstructed the underlying time-to-event data, and calculated (log) HRs and standard errors using 
a Cox regression model.7 Correlation between progression-free and overall survival within the two trials included 
in the meta-analysis8,9 that provided sufficient data was calculated by Spearman's rank correlation coefficient. A 
between-outcome correlation of 0.8 was finally used. Sensitivity analyses showed robustness of the analysis. 
 
Table S1: Current ESMO and NCCN guidelines on consolidation radiotherapy for DLBCL 
Compilation of the current guidelines of ESMO (Tilly, 2015)10 and NCCN (National Comprehensive Cancer 
Network. NCCN Clinical Practice Guidelines in Oncology: B-cell lymphomas, version 6.2019: 
https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf (Accessed Nov 28, 2019)) on the use of the 
consolidation radiotherapy for patients with DLBCL.  
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Society Indication No indication Unclear
ESMO Young, low risk, aaIPI 0, bulky disease (R-CHOP) Young, low risk, aaIPI 0, non-bulky disease Young intermediate to high risk (aa-IPI > 2)
Consider in stage I&II, (non)bulky, partial response or EoT PET+ When a complete response is achieved no firm indicationNCCN
